Equity Overview
Price & Market Data
Price: $8.20
Daily Change: +$2.77 / 33.78%
Range: $5.44 - $12.37
Market Cap: $20,350,500
Volume: 7,996,768
Performance Metrics
1 Week: 44.80%
1 Month: 21.75%
3 Months: -10.84%
6 Months: -56.88%
1 Year: -82.08%
YTD: -35.93%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.